New jab to fight severe asthma backed by NICE

GPs should refer patients with severe asthma to specialist care for treatment with omalizumab (Xolair), according to latest NICE guidance.

The NICE technology appraisal recommends the use of omalizumab for the treatment of severe persistent allergic asthma in adults and adolescents over the age of 12.

It is estimated that around 6,000 patients in the UK will be able to benefit from the drug, which is already available in Scotland.

Patients in England and Wales can expect the drug to become available within the next three months, with confirmation that the drug will be made available in Northern Ireland expected next month.

Omalizumab, which is given as a jab twice a month, should only be initiated if the patient has confirmation of IgE mediated allergy to a perennial allergen by clinical history and allergy skin testing.

GPs should only refer patients for the treatment if they have suffered two or more severe asthma attacks requiring hospital admission within the previous year, and a further two attacks which required treatment or monitoring in excess of the patient's usual regimen.

Treatment should be stopped if patients fail to show any adequate response after 16 weeks.

Glasgow GP Dr John Haughney, president of the International Primary Care Group, said: 'The drug can be life-transforming for asthmatic patients who have failed on treatments like oral steroids.

'Every practice is likely to have patients with severe asthma that will benefit from the drug.'

Dr Steve Holmes, chairman of the General Practice Airways Group and a GP in Somerset, said: 'It's important that GPs refer the patients that would benefit from the drug on to specialist centres to optimise its use.'

Neil Churchill, chief executive of the charity Asthma UK, described NICE's decision as a 'victory for people with severe allergic asthma'.

'Existing asthma treatments just do not work for around half a million people across the UK living with difficult to control asthma,' he said.

sanjay.tanday@haymarket.com

NICE guidance

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women, children and under-18s will not be recommended for routine COVID-19...

GP training: How an audit e-portfolio log entry is assessed

GP training: How an audit e-portfolio log entry is assessed

The second of two articles on audit during GP training looks at how the quality improvement...

GP training: Writing up an audit for your e-portfolio

GP training: Writing up an audit for your e-portfolio

In the first of two articles on how to write up an audit, a typical e-portfolio entry...

UK ups order of 95% effective COVID-19 vaccine by 2m doses

UK ups order of 95% effective COVID-19 vaccine by 2m doses

The UK has increased its order of the 95% effective Moderna COVID-19 vaccine to 7m...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Which COVID-19 vaccines are lined up for roll-out on the NHS?

Which COVID-19 vaccines are lined up for roll-out on the NHS?

As GPs and their teams prepare for delivering a COVID-19 vaccination programme that...